A Neurofeedback Interface in Poststroke Neuromodulation Using TMS-fNIRS
Development and Validation of an Adaptive Neurofeedback Interface Using Transcranial Magnetic Stimulation to Modulate Cortical Excitability
1 other identifier
interventional
100
1 country
2
Brief Summary
Stroke is a type of cerebrovascular disease, and the primary characteristic of post-stroke brains is pathological changes in cerebral hemodynamics. Therefore, hemodynamic signals may provide straightforward information for guiding post-stroke neuromodulation therapy. Transcranial magnetic stimulation (TMS), a non-invasive neurostimulation modality, has been extensively used in post-stroke rehabilitation. However, current TMS-based neuromodulation therapy demonstrates a large treatment response variability due to its open-loop nature. To address this challenge, the research team will develop a novel form of closed-loop neurofeedback interfaces which controls the timing of TMS pulses precisely based on neural biomarkers from functional near-infrared spectroscopy (fNIRS) and test the accuracy of the adaptive neurofeedback system in healthy adults. After establishing the TMS-based neurofeedback interface, a proof-of-concept study enrolling postacute stroke patients will be performed to evaluate the efficacy of the TMS neurofeedback interface in enhancing motor control of the hemiplegic upper extremity and cortical excitability of the ipsilesional motor cortex. These findings will verify whether the proposed fNIRS-controlled TMS neurofeedback interface can be clinically feasible as a form of post-stroke neuromodulation therapy. Additionally, the results will significantly contribute to the scientific understanding of how neuromodulation improves hemodynamic signals in a closed-loop manner, thereby enhancing functional recovery in poststroke survivors.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable stroke
Started Aug 2025
Longer than P75 for not_applicable stroke
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 20, 2025
CompletedFirst Posted
Study publicly available on registry
July 28, 2025
CompletedStudy Start
First participant enrolled
August 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 30, 2028
March 3, 2026
July 1, 2025
2.4 years
July 20, 2025
March 1, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Motor evoked potential
Motor Evoked Potentials (MEPs) are electrical signals generated by stimulating the motor cortex and recorded from the peripheral muscle (e.g., a hand muscle). This is a measure of corticospinal excitability.
Baseline
Study Arms (2)
functional near-infrared spectroscopy (fNIRS)-triggered TMS
EXPERIMENTALThe TMS will be triggered based on individualized fNIRS signals from the participants. Specifically, the TMS will be triggered during high-excitability phase of fNIRS hemodynamic response during motor imagination.
TMS
ACTIVE COMPARATORThe TMS will be triggered by the operator according to a pre-defined protocol
Interventions
The firing of TMS will be triggered according to fNIRS signal intensity.
Eligibility Criteria
You may qualify if:
- Participants who meet the following criteria will be included:
- Diagnosed with ischemic subcortical stroke, with stroke onset≥6 months.
- Age between 18 and 80 years.
- Residual upper limb functions between levels 2-7 in the FTHUE.
- Capable of providing informed written consent.
- Capable of reading and communicating with Chinese.
You may not qualify if:
- Patients who meet any of the following criteria will be excluded:
- any contraindications to TMS (screened by the safety checklist by Rossi).
- signs of cognitive impairment, with a Montreal cognitive assessment score\<21/22 out of 30.
- any moderate-to-severe chronic illness, such as uncontrolled hypertension, heart disease or renal failure.
- Healthy participants should be aged between 18 and 80, with no known history of neurological diseases. They should not have any moderate-to-severe chronic illness, such as uncontrolled hypertension, heart disease or renal failure.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The Hong Kong Polytechnic Universitylead
- RWTH Aachen Universitycollaborator
Study Sites (2)
Hong Kong Polytechnic University
Hong Kong, 000000, Hong Kong
Hong Kong Polytechnic University - Brain Stimulation Laboratory
Hong Kong, Hong Kong
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 20, 2025
First Posted
July 28, 2025
Study Start
August 1, 2025
Primary Completion (Estimated)
December 30, 2027
Study Completion (Estimated)
December 30, 2028
Last Updated
March 3, 2026
Record last verified: 2025-07